Plain-English translation of NCT04390724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing Yttrium-90 (Y90) radioembolization, a treatment that uses tiny radioactive beads to target liver cancer tumors. The goal is to find the best dose of Y90 that will help the healthy liver grow larger, so surgeons can then safely remove the part of your liver that has cancer. This treatment may also help patients who currently don't have enough healthy liver remaining to make surgery possible.
Some liver cancer patients don't have enough healthy liver left after their tumor to safely remove it surgically. This medication has been shown to make the remaining healthy liver grow, but doctors aren't sure what the ideal dose is to get the best growth with the safest results.
You likely qualify if…
You likely don't qualify if…
If you join Group 1, you will receive the standard Y90 radiation treatment and may have an optional liver biopsy. If you are in Group 2, you will receive Y90 treatment at the optimal dose found in Group 1, and you'll have blood tests and special MRI scans done at specific timepoints. The active study phase lasts up to 3 months, and researchers will follow your health for up to 5 years afterward.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
United States
Sponsor
Northwestern University
Collaborators
Mayo Clinic
Enrollment target
~104 participants
Started
July 2020
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Robert Lewandowski, MD
Northwestern University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.